Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06164717 · ClinicalTrials.gov registry record · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
A NA study of Speech, sponsored by University of Washington.
- Recruiting
- Registry status
- NA
- Development phase
- 507
- Enrollment target
- 1
- Study location
NCT06164717: Recruiting NA study of Speech, sponsored by University of Washington.
NCT06164717 is a NA study of Speech that is actively recruiting participants, run by University of Washington. The registered enrollment target is 507 participants, above the 119-participant average among 9 other Speech trials with a reported enrollment target (326% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06164717, a NA study of Speech, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- NA
- Development phase
- 507 participants
- Enrollment target
- 1
- Study location
Study Summary
This study meets the NIH definition of a clinical trial, but is not a treatment study. Instead, the goal of this study is to investigate how hearing ourselves speak affects the planning and execution of speech movements. The study investigates this topic in both typical speakers and in patients with Deep Brain Stimulation (DBS) implants. The main questions it aims to answer are: * Does the way we hear our own speech while talking affect future speech movements? * Can the speech of DBS patients reveal which brain areas are involved in adjusting speech movements? Participants will read words, sentences, or series of random syllables from a computer monitor while their speech is being recorded. For some participants, an electrode cap is also used to record brain activity during these tasks. And for DBS patients, the tasks will be performed with the stimulator ON and with the stimulator OFF.
Primary Outcome
The frequencies of the subject's first two formants (F1, F2) for each test word will be measured from spectrographic displays with overlaid Linear Predictive Coding formant tracks.
Conditions Studied
Interventions
- BEHAVIORAL Auditory feedback perturbation during speech
- BEHAVIORAL Visual feedback perturbation during reaching
- OTHER DBS stimulation ON/OFF
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT06164717 shows while recruiting
NCT06164717 is an interventional study that assigns participants to a tested intervention. The registered 507 participants enrollment target is mid-sized for trials with a published cap, above the 119-participant average among 9 other Speech trials with a reported enrollment target (326% higher).
The record links to 1 condition, with Speech appearing as the primary indexed condition, and to 3 interventions - of which Auditory feedback perturbation during speech is the first listed.
NCT06164717 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06164717 about?
NCT06164717 is a clinical study titled "Behavioral and Neural Characteristics of Adaptive Speech Motor Control". This study meets the NIH definition of a clinical trial, but is not a treatment study. Instead, the goal of this study is to investigate how hearing ourselves speak affects the planning and execution of speech movements. The study investigates this topic in both typical speakers and in patients with...
What is the current status of trial NCT06164717?
This trial is currently recruiting. It is a NA study. The enrollment target is 507 participants. The study started on 2023-01-01. Estimated completion is 2027-12-31.
What conditions does trial NCT06164717 study?
This clinical trial studies the following conditions: Speech.
What interventions are being tested in trial NCT06164717?
The interventions under investigation include: Auditory feedback perturbation during speech (BEHAVIORAL), Visual feedback perturbation during reaching (BEHAVIORAL), DBS stimulation ON/OFF (OTHER).
Who is sponsoring clinical trial NCT06164717?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06164717 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Speech
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06164717's enrollment target sits among peer trials
507 1st of 9 higher than 9 of 9 other Speech trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Speech trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vowel Space Expansion Sensorimotor Adaptation
RECRUITING · NA
-
Speech Motor Learning and Retention (Aim 1)
RECRUITING · NA
-
Speech Motor Learning and Retention (Aim 2)
RECRUITING · NA
-
Effects of Clear Speech on Listening Effort and Memory in Sentence Processing
RECRUITING · NA
-
Talk With Me Baby to Enhance the Early Home Language Environment
RECRUITING · NA
-
Social Influences on Sensorimotor Integration of Speech Production and Perception During Early Vocal Learning
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- NCT07484217 · 508 participants · Phase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI